261 related articles for article (PubMed ID: 32033147)
21. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
Yoon HY; Kim DS; Song JW
Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
[TBL] [Abstract][Full Text] [Related]
23. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.
Inomata M; Nishioka Y; Azuma A
Core Evid; 2015; 10():89-98. PubMed ID: 26346347
[TBL] [Abstract][Full Text] [Related]
24. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
[TBL] [Abstract][Full Text] [Related]
25. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
[TBL] [Abstract][Full Text] [Related]
26. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.
Ogura T; Inoue Y; Azuma A; Homma S; Kondoh Y; Tanaka K; Ochiai K; Sugiyama Y; Nukiwa T
Adv Ther; 2023 Apr; 40(4):1474-1493. PubMed ID: 36692681
[TBL] [Abstract][Full Text] [Related]
27. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
28. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data.
Khan MA; Sherbini N; Alyami S; Al-Harbi A; Al-Ghamdi M; Alrajhi S; Rajendram R; Al-Jahdali H
Ann Thorac Med; 2023; 18(1):45-51. PubMed ID: 36968327
[TBL] [Abstract][Full Text] [Related]
29. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
30. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.
Chianese M; Screm G; Salton F; Confalonieri P; Trotta L; Barbieri M; Ruggero L; Mari M; Reccardini N; Geri P; Hughes M; Lerda S; Confalonieri M; Mondini L; Ruaro B
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931376
[TBL] [Abstract][Full Text] [Related]
31. A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.
Harari S; Caminati A; Poletti V; Confalonieri M; Gasparini S; Lacedonia D; Luppi F; Pesci A; Sebastiani A; Spagnolo P; Vancheri C; Balestro E; Bonifazi M; Cerri S; De Giacomi F; Della Porta R; Foschino Barbaro MP; Fui A; Pasquinelli P; Rosso R; Tomassetti S; Specchia C; Rottoli P;
Respiration; 2018; 95(6):433-440. PubMed ID: 29587263
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.
Tzouvelekis A; Karampitsakos T; Kontou M; Granitsas A; Malliou I; Anagnostopoulos A; Ntolios P; Tzilas V; Bouros E; Steiropoulos P; Chrysikos S; Dimakou K; Koulouris N; Bouros D
Pulm Pharmacol Ther; 2018 Apr; 49():61-66. PubMed ID: 29366978
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
Yoon HY; Park S; Kim DS; Song JW
Respir Res; 2018 Oct; 19(1):203. PubMed ID: 30340638
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
Khalil N; Manganas H; Ryerson CJ; Shapera S; Cantin AM; Hernandez P; Turcotte EE; Parker JM; Moran JE; Albert GR; Sawtell R; Hagerimana A; Laurin P; Gagnon L; Cesari F; Kolb M
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578394
[TBL] [Abstract][Full Text] [Related]
35. Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis.
Hughes G; Toellner H; Morris H; Leonard C; Chaudhuri N
J Clin Med; 2016 Sep; 5(9):. PubMed ID: 27598213
[TBL] [Abstract][Full Text] [Related]
36. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.
Uchida Y; Ikeda S; Sekine A; Katano T; Tabata E; Oda T; Okuda R; Kitamura H; Baba T; Komatsu S; Ogura T
Respir Investig; 2021 Jan; 59(1):99-105. PubMed ID: 32891571
[TBL] [Abstract][Full Text] [Related]
37. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.
Vancheri C; Sebastiani A; Tomassetti S; Pesci A; Rogliani P; Tavanti L; Luppi F; Harari S; Rottoli P; Ghirardini A; Kirchgaessler KU; Albera C
Respir Med; 2019 Sep; 156():78-84. PubMed ID: 31445389
[TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Ogura T; Taniguchi H; Azuma A; Inoue Y; Kondoh Y; Hasegawa Y; Bando M; Abe S; Mochizuki Y; Chida K; Klüglich M; Fujimoto T; Okazaki K; Tadayasu Y; Sakamoto W; Sugiyama Y
Eur Respir J; 2015 May; 45(5):1382-92. PubMed ID: 25504994
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.
Skandamis A; Kani C; Markantonis SL; Souliotis K
J Drug Assess; 2019; 8(1):55-61. PubMed ID: 31044096
[No Abstract] [Full Text] [Related]
40. A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world.
Nakamura M; Okamoto M; Fujimoto K; Ebata T; Tominaga M; Nouno T; Zaizen Y; Kaieda S; Tsuda T; Kawayama T; Hoshino T
Ann Transl Med; 2019 Jun; 7(12):262. PubMed ID: 31355229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
